Noble Financial Begins Coverage on Gyre Therapeutics (NASDAQ:GYRE)

Investment analysts at Noble Financial started coverage on shares of Gyre Therapeutics (NASDAQ:GYRE) in a research report issued on Tuesday, Marketbeat.com reports. The firm set an “outperform” rating on the stock.

Gyre Therapeutics Stock Up 2.8 %

Shares of NASDAQ:GYRE opened at $11.67 on Tuesday. Gyre Therapeutics has a one year low of $8.26 and a one year high of $19.96. The company has a 50-day simple moving average of $11.24 and a 200-day simple moving average of $12.32.

Insider Activity at Gyre Therapeutics

In other news, President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 34,054 shares of company stock worth $383,057 over the last 90 days. Company insiders own 19.52% of the company’s stock.

Institutional Trading of Gyre Therapeutics

Several large investors have recently bought and sold shares of GYRE. Geode Capital Management LLC increased its position in Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Gyre Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock valued at $1,386,000 after purchasing an additional 918 shares in the last quarter. State Street Corp raised its position in Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after purchasing an additional 8,412 shares during the period. Northern Trust Corp increased its stake in Gyre Therapeutics by 9.1% during the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock worth $1,251,000 after buying an additional 8,624 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new stake in Gyre Therapeutics during the 4th quarter worth approximately $1,225,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.